Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ADVB Stock Alerts

Advanced Biomed (ADVB) Competitors

Advanced Biomed logo
$4.40 -0.03 (-0.68%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$4.53 +0.13 (+2.86%)
As of 05/15/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ADVB vs. CCM, PIII, BMGL, ACON, and MRAI

Should you buy Advanced Biomed stock or one of its competitors? MarketBeat compares Advanced Biomed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Advanced Biomed include Concord Medical Services (CCM), P3 Health Partners (PIII), Basel Medical Group (BMGL), Aclarion (ACON), and Marpai (MRAI). These companies are all part of the "healthcare" industry.

How does Advanced Biomed compare to Concord Medical Services?

Advanced Biomed (NASDAQ:ADVB) and Concord Medical Services (NYSE:CCM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Advanced Biomed's return on equity of 92.11% beat Concord Medical Services' return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced BiomedN/A 92.11% 58.03%
Concord Medical Services N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Concord Medical Services
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Advanced Biomed has higher earnings, but lower revenue than Concord Medical Services.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced BiomedN/AN/A-$3.26M$4.820.91
Concord Medical Services$460.51M0.05-$13.27MN/AN/A

In the previous week, Advanced Biomed had 1 more articles in the media than Concord Medical Services. MarketBeat recorded 3 mentions for Advanced Biomed and 2 mentions for Concord Medical Services. Advanced Biomed's average media sentiment score of 1.48 beat Concord Medical Services' score of 0.37 indicating that Advanced Biomed is being referred to more favorably in the media.

Company Overall Sentiment
Advanced Biomed Positive
Concord Medical Services Neutral

Advanced Biomed has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Concord Medical Services has a beta of -1.09, suggesting that its stock price is 209% less volatile than the broader market.

Summary

Advanced Biomed beats Concord Medical Services on 6 of the 7 factors compared between the two stocks.

How does Advanced Biomed compare to P3 Health Partners?

P3 Health Partners (NASDAQ:PIII) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Advanced Biomed has a net margin of 0.00% compared to P3 Health Partners' net margin of -8.57%. Advanced Biomed's return on equity of 92.11% beat P3 Health Partners' return on equity.

Company Net Margins Return on Equity Return on Assets
P3 Health Partners-8.57% -302.33% -19.87%
Advanced Biomed N/A 92.11%58.03%

P3 Health Partners currently has a consensus target price of $10.33, suggesting a potential downside of 8.47%. Given P3 Health Partners' stronger consensus rating and higher possible upside, equities research analysts plainly believe P3 Health Partners is more favorable than Advanced Biomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Advanced Biomed has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
P3 Health Partners$1.46B0.06-$147.95M-$38.60N/A
Advanced BiomedN/AN/A-$3.26M$4.820.91

In the previous week, P3 Health Partners had 18 more articles in the media than Advanced Biomed. MarketBeat recorded 21 mentions for P3 Health Partners and 3 mentions for Advanced Biomed. Advanced Biomed's average media sentiment score of 1.48 beat P3 Health Partners' score of 0.24 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company Overall Sentiment
P3 Health Partners Neutral
Advanced Biomed Positive

7.8% of P3 Health Partners shares are held by institutional investors. 17.8% of P3 Health Partners shares are held by insiders. Comparatively, 34.4% of Advanced Biomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

P3 Health Partners has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Summary

Advanced Biomed beats P3 Health Partners on 9 of the 15 factors compared between the two stocks.

How does Advanced Biomed compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Advanced Biomed's return on equity of 92.11% beat Basel Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Basel Medical GroupN/A N/A N/A
Advanced Biomed N/A 92.11%58.03%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Advanced Biomed has lower revenue, but higher earnings than Basel Medical Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Basel Medical Group$8.90M1.39-$9.50MN/AN/A
Advanced BiomedN/AN/A-$3.26M$4.820.91

In the previous week, Advanced Biomed had 2 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for Advanced Biomed and 1 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 1.87 beat Advanced Biomed's score of 1.48 indicating that Basel Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Basel Medical Group Very Positive
Advanced Biomed Positive

Basel Medical Group has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Summary

Advanced Biomed beats Basel Medical Group on 5 of the 7 factors compared between the two stocks.

How does Advanced Biomed compare to Aclarion?

Aclarion (NASDAQ:ACON) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Advanced Biomed has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Advanced Biomed's return on equity of 92.11% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
Aclarion-10,320.51% -54.41% -51.71%
Advanced Biomed N/A 92.11%58.03%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclarion
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Aclarion had 5 more articles in the media than Advanced Biomed. MarketBeat recorded 8 mentions for Aclarion and 3 mentions for Advanced Biomed. Advanced Biomed's average media sentiment score of 1.48 beat Aclarion's score of 1.15 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company Overall Sentiment
Aclarion Positive
Advanced Biomed Positive

Advanced Biomed has lower revenue, but higher earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$80K97.17-$7.23M-$9.03N/A
Advanced BiomedN/AN/A-$3.26M$4.820.91

Aclarion has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

7.5% of Aclarion shares are held by institutional investors. 0.8% of Aclarion shares are held by company insiders. Comparatively, 34.4% of Advanced Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Advanced Biomed beats Aclarion on 8 of the 12 factors compared between the two stocks.

How does Advanced Biomed compare to Marpai?

Marpai (NASDAQ:MRAI) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Advanced Biomed has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Advanced Biomed's return on equity of 92.11% beat Marpai's return on equity.

Company Net Margins Return on Equity Return on Assets
Marpai-85.70% N/A -100.23%
Advanced Biomed N/A 92.11%58.03%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marpai
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Marpai and Marpai both had 3 articles in the media. Advanced Biomed's average media sentiment score of 1.48 beat Marpai's score of 0.00 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company Overall Sentiment
Marpai Neutral
Advanced Biomed Positive

Advanced Biomed has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marpai$34.87M0.21-$28.75M-$0.95N/A
Advanced BiomedN/AN/A-$3.26M$4.820.91

Marpai has a beta of 4.38, meaning that its share price is 338% more volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

49.8% of Marpai shares are held by institutional investors. 46.1% of Marpai shares are held by company insiders. Comparatively, 34.4% of Advanced Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Advanced Biomed beats Marpai on 8 of the 12 factors compared between the two stocks.

Get Advanced Biomed News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADVB vs. The Competition

Export
MetricAdvanced BiomedServices – Health IndustryServices SectorNASDAQ Exchange
Market Cap$6.00M$1.37B$1.01B$12.30B
Dividend YieldN/AN/A5.07%5.26%
P/E Ratio0.9112.6010.4725.27
Price / SalesN/A6.0121.9762.46
Price / CashN/A3,198.37416.2054.86
Price / Book1.374.463.266.90
Net Income-$3.26M-$26.94M-$2.50M$334.66M
7 Day Performance-28.92%-6.68%-5.46%0.12%
1 Month Performance-8.33%-4.40%-1.88%-0.18%
1 Year PerformanceN/AN/A21.87%30.62%

Advanced Biomed Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADVB
Advanced Biomed
1.2967 of 5 stars		$4.40
-0.7%		N/AN/A$6.00MN/A0.9140
CCM
Concord Medical Services
0.5602 of 5 stars		$4.91
+1.1%		N/A-38.7%$21.06M$65.85MN/A970
PIII
P3 Health Partners
1.13 of 5 stars		$2.86
-1.0%		$3.50
+22.4%		+41.3%$20.85M$1.46BN/A500
BMGL
Basel Medical Group
0.5254 of 5 stars		$0.70
+14.8%		N/A-72.3%$11.40M$8.90MN/A36
ACON
Aclarion
1.2322 of 5 stars		$3.28
+2.5%		N/A-54.5%$7.88M$80KN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ADVB) was last updated on 5/17/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX Goes Public. Here's What Happens To Your IRA.
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel